aspirin and osimertinib

aspirin has been researched along with osimertinib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Han, R; Hao, S; He, Y; Hu, C; Li, L; Lin, C; Lu, C; Wang, Y; Zhang, C1
Fang, B; He, Y; Heymach, JV; Hong, L; Hubert, SM; Jack Lee, J; Le, X; Lewis, J; Liu, X; Nilsson, M; Rinsurongkawong, W; Roth, J; Spelman, A; Swisher, S; Wu, S; Zhang, J1

Other Studies

2 other study(ies) available for aspirin and osimertinib

ArticleYear
Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
    Molecular oncology, 2020, Volume: 14, Issue:6

    Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Animals; Apoptosis; Aspirin; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forkhead Box Protein O3; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Proto-Oncogene Proteins c-akt; Signal Transduction; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays

2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 149

    Topics: Acrylamides; Aniline Compounds; Aspirin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies

2020